We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

vrijdag 24 februari 2017

The Lancet: [News] Service review: improving breast cancer care in Tanzania

[News] Service review: improving breast cancer care in Tanzania
Measures to improve the diagnosis and treatment of breast cancer in Tanzania should focus on women with symptomatic disease, according to the first assessment of current capacity in breast cancer care and achievable priorities for future improvements. The authors of the Tanzania Breast Health Care Assessment 2017 identified an early detection programme with accurate diagnostic facilities and timely access to effective treatments as key measures for the improvement of breast cancer outcomes.
Read more

[News] Scalp cooling and hair loss during breast cancer chemotherapy
An interim analysis of the first randomised controlled phase 3 trial of a scalp-cooling device in women with stage I and II breast cancer undergoing chemotherapy shows that the device successfully prevents hair loss. The device is used during chemotherapy and for a short time before and after treatment.
Read more

[News] Pembrolizumab as second-line treatment for urothelial cancer
Pembrolizumab could improve overall survival in patients with urothelial cancer that has progressed or recurred after platinum-based chemotherapy, according to the results of a phase 3 trial.
Read more

[Articles] Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study
This population-based analysis reveals that carcinoid syndrome is significantly associated with tumour grade, stage, and primary tumour site, and leads to shorter survival compared with those patients without carcinoid syndrome. An improved understanding of the heterogeneity of presenting symptoms among patients with NETs might permit more tailored assessment and management than at present and enable future research into the effect of carcinoid syndrome control on patient survival.
Read more

[Comment] Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer
De-intensification of breast cancer treatment is a laudable goal. Fewer aggressive breast and axillary surgeries are now needed to achieve excellent outcomes, and genomic assays can help to identify patients in whom adjuvant chemotherapy can be omitted.1 Although chemotherapy remains the backbone on which HER2-targeted therapy is used in patients with early-stage HER2-positive breast cancer, treatment de-intensification in these patients is receiving increasing attention. Non-anthracycline-based chemotherapy is now part of the standard of care, and shorter courses of chemotherapy can be appropriate in the management of early-stage, node-negative, HER2-positive breast cancer.
Read more